Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Strober

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2022
Pharmacology of orismilast, a potent and selective PDE4 inhibitorJonathan I Silverberg, Lars E French, Richard B Warren, et al.
The Journal of Clinical and Aesthetic Dermatology|October 28, 2015
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingSeemal R Desai, Ilona J Frieden, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
The British Journal of Dermatology|February 8, 2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trialsGeorgios Kokolakis, Richard B Warren, Bruce Strober, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
Dermatologic Therapy|January 25, 2021
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis RegistryBenjamin Lockshin, Angel Cronin, Ryan W Harrison, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|June 30, 2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialBruce Strober, Linda Stein Gold, Robert Bissonnette, et al.
Dermatology and Therapy|January 21, 2021
Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis RegistryAlice B Gottlieb, Joseph F Merola, Joshua Cirulli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2022
Pharmacology of orismilast, a potent and selective PDE4 inhibitorJonathan I Silverberg, Lars E French, Richard B Warren, et al.
The Journal of Clinical and Aesthetic Dermatology|October 28, 2015
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingSeemal R Desai, Ilona J Frieden, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.
Dermatology and Therapy|August 8, 2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD StudyAlexa B Kimball, Dimittri Delevry, Min Yang, et al.
The British Journal of Dermatology|February 8, 2023
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trialsGeorgios Kokolakis, Richard B Warren, Bruce Strober, et al.
Journal of the American Academy of Dermatology|November 6, 2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)Bruce Strober, Melinda Gooderham, Elke M G J de Jong, et al.
Dermatologic Therapy|January 25, 2021
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis RegistryBenjamin Lockshin, Angel Cronin, Ryan W Harrison, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2025
Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trialTadashi Terui, Yukari Okubo, Satomi Kobayashi, et al.
Pageof 13